Tesamorelin in Australia: Research Guide & Where to Buy

Tesamorelin is a synthetic 44-amino acid polypeptide analogue of human Growth Hormone-Releasing Hormone (GHRH), developed by Theratechnologies Inc. and approved by the FDA in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

Its key structural distinction from native GHRH is an N-terminal modification, the addition of a trans-3-hexenoic acid group, which protects the peptide from rapid degradation by DPP-IV enzymes. Native GHRH has a circulating half-life of approximately 5–7 minutes; Tesamorelin's modification substantially extends its pharmacological window, making once-daily dosing viable.

Tesamorelin is notable for being one of the very few synthetic GHRH analogues to have completed large Phase 3 clinical trials and received regulatory approval in a major jurisdiction, giving it an unusually robust evidence base compared to most research peptides.

Tesamorelin binds to and activates GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. This GH pulse then drives hepatic production of IGF-1, which mediates many downstream anabolic and metabolic effects.

A key feature of Tesamorelin's mechanism is that it preserves the natural hypothalamic-pituitary-GH axis feedback loop. Unlike direct HGH administration, which bypasses the pituitary entirely and can suppress endogenous GH production, Tesamorelin works upstream, the physiological somatostatin feedback mechanism remains intact, limiting the risk of supraphysiological GH overshoot.

This pulsatile, feedback-preserved pattern of GH stimulation is what distinguishes GHRH analogues as a class from exogenous somatropin, and is a primary reason researchers studying GH axis dynamics favour them for certain research designs.

Tesamorelin has an unusually strong clinical evidence base for a research peptide, with Phase 3 trial data across multiple endpoints:

• Visceral adipose tissue (VAT) reduction (Phase 3 trials (Falutz et al., 2010, J Acquir Immune Defic Syndr) demonstrated mean VAT reductions of approximately 15–18% over 26 weeks in HIV-infected patients with lipodystrophy versus placebo. This represents one of the only pharmacological interventions shown to specifically reduce visceral fat) the metabolically active fat depot most strongly associated with cardiovascular and metabolic disease risk.
• Hepatic fat reduction, research has demonstrated approximately 37% relative reduction in liver fat content in treated groups, with implications for NAFLD/NASH research models.
• IGF-1 elevation, Tesamorelin consistently elevates serum IGF-1 in treated subjects, with IGF-1 returning to baseline after discontinuation. This reversibility is an important feature for research designs requiring controlled IGF-1 modulation.
• Lipid profiles (studies have reported improvements in triglyceride levels and trig-to-HDL ratios in Tesamorelin groups, with elevated adiponectin) an adipokine associated with improved insulin sensitivity.
• Cognitive function, a separate research programme (Baker et al., 2012, Archives of Neurology) investigated Tesamorelin in models of mild cognitive impairment in older adults, finding improvements in cognitive function scores. GH and IGF-1 receptors are expressed in hippocampal and cortical tissue; this research area remains active.
• Cardiovascular risk, a 2025 analysis published in Open Forum Infectious Diseases reported significant reductions in cardiovascular disease risk prediction scores in Tesamorelin treatment arms from Phase 3 studies.

Importantly, Tesamorelin's benefits on visceral fat reverse after discontinuation, fat reaccumulates when administration stops. This is a critical variable for long-term research designs and interpreting what "sustained effect" means with this compound.

Tesamorelin occupies a distinct position among GHRH analogues available for research:

Tesamorelin's full 44-amino acid sequence (matching endogenous GHRH) and its Phase 3 clinical data set it apart from shorter GHRH fragments. For researchers specifically studying visceral adiposity, hepatic fat metabolism, or requiring a GHRH analogue with the most robust human evidence base, Tesamorelin is the most validated choice in the class.

Tesamorelin is studied in combination with other peptides in research models targeting complementary pathways:

• Tesamorelin + Ipamorelin, combining a GHRH analogue with a GHRP produces synergistic GH release via dual receptor activation; Tesamorelin's longer sequence may offer different downstream effects compared to CJC-1295 in this context
• Tesamorelin + BPC-157 / TB-500, Tesamorelin drives metabolic and GH-axis effects while tissue repair peptides address structural recovery; studied in combined performance and recovery research models

See also: CJC-1295 + Ipamorelin research guide →

OzPeps supplies research-grade Tesamorelin 10mg Australia-wide with fast dispatch, discreet packaging, and crypto payment options (BTC, LTC, XMR).

View Tesamorelin 10mg stock and pricing →

Tesamorelin supplied by OzPeps is for laboratory and in-vitro research purposes only. While Tesamorelin holds FDA approval as Egrifta for a specific therapeutic indication in the United States, it is not TGA-approved as a therapeutic good in Australia in this context and is not intended for human or animal administration outside approved clinical settings. Researchers are responsible for compliance with all applicable regulations.